STOCK MARKET BSE NSE

Dr Reddy's launches anti-epilepsy drug in US market

The drug has been approved by the US Food and Drug Administration (USFDA).

Published: 19th June 2018 04:19 PM  |   Last Updated: 19th June 2018 04:19 PM   |  A+A-

Image for representational purpose only.

By PTI

HYDERABAD: Dr Reddy's Laboratories Ltd today announced that it has launched antiepileptic drug, Levetiracetram in Sodium Chloride injection, in multiple strengths, in the US market.

The drug maker launched Levetiracetram in Sodium Chloride Injection in 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation's Levetiracetam in Sodium Chloride Injection.

The drug has been approved by the US Food and Drug Administration (USFDA), a press release from Dr Reddy's said.

The Levetiracetam in Sodium Chloride Injection brand and generic had US sales of approximately USD 37 million moving annual turnover for the most recent twelve months ending in April 2018, according to IMS Health, the release said.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp